子宮がん診断の市場レポート：2030年までの動向、予測、競合分析

子宮がん診断の動向と予測

世界の子宮がん診断市場は、2024年から2030年までのCAGRが9.0%で、2030年までに推定112億米ドルに達すると予測されます。この市場の主な促進要因は、子宮がん患者の増加、子宮がん診断の技術進歩、世界の女性の肥満傾向の拡大です。世界の子宮がん診断市場の将来は、病院、診断センター、がん研究センター市場に機会があり、有望視されています。

Lucintelの予測では、画像診断技術の進化により精度が向上しているため、機器ベースの市場が予測期間中に高い成長を遂げる見込みです。

この市場では、がん患者の増加、低侵襲の高度なスクリーニング技術に対する需要の高まり、病院におけるがん診断への投資や資金調達の増加により、病院が引き続き最大セグメントとなります。

北米は、米国における子宮がんの罹患率の増加、がんと闘うためのタイムリーな発見と予防措置の重要性の強調、政府によるさまざまながん啓発プログラムの増加により、予測期間中最大の地域であり続けると思われます。

よくある質問

Q.1子宮がん診断の市場規模は？

A1.世界の子宮がん診断市場は、2030年までに推定112億米ドルに達すると予想されています。

Q.2子宮がん診断市場の成長予測は？

A2.世界の子宮がん診断市場は、2024年から2030年にかけてCAGR 9.0％で成長すると予測されます。

Q.3子宮がん診断市場の成長に影響を与える主な促進要因は何ですか？

A3.この市場の主な促進要因は、子宮がん症例の増加、子宮がん診断の技術進歩、世界の女性の肥満の蔓延です。

Q4.市場の主要セグメントは：

A4.子宮がん診断薬市場の将来は、病院、診断センター、がん研究センター市場において有望です。

Q5.市場の主要企業は：

A5.主要な子宮がん診断企業は以下の通りです：

• Siemens Healthcare
• Narang Medical
• F-Hoffmann La Roche
• Esaote
• Samsung Medison
• Olympus
• Arquer Diagnostics
• Guzip Biomarkers
• General Electric
• Canon Medical

Q6.今後、最大となる市場セグメントは：

A6.Lucintelは、画像診断技術の進化により精度が向上し、機器ベースの市場が予測期間中に高い成長を示すと予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は：

A7.北米は、米国における子宮がん罹患率の増加、タイムリーな発見とがんと闘うための予防措置の重要性の強調、政府による様々ながん啓発プログラムの増加により、予測期間中最大の地域であり続けます。

Q8.レポートのカスタマイズは可能か：

A8.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の子宮がん診断市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の子宮がん診断市場の動向（2018～2023年）と予測（2024～2030年）
• 診断タイプ別世界の子宮がん診断市場
  • 機器ベース
  • 処置ベース
• 子宮がん診断市場（タイプ別）
  • 子宮内膜がん
  • 子宮肉腫
• 年齢層別世界の子宮がん診断市場
  • 30歳未満
  • 31～40歳
  • 41～50歳
  • 51～60歳
  • 60歳超
• 最終用途別世界の子宮がん診断市場
  • 病院
  • 診断センター
  • がん研究センター
  • その他

第4章 2018年から2030年までの地域別市場動向と予測分析

• 地域別子宮がん診断市場
• 北米の子宮がん診断市場
• 欧州子宮がん診断市場
• アジア太平洋地域の子宮がん診断市場
• その他地域子宮がん診断市場

第5章 競合分析

• 製品ポートフォリオ分析
• 業務統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 診断タイプ別の世界の子宮がん診断市場の成長機会
  • 世界の子宮がん診断市場における成長機会（タイプ別）
  • 年齢層別の世界の子宮がん診断市場の成長機会
  • 最終用途別の世界の子宮がん診断市場の成長機会
  • 地域別の世界の子宮がん診断市場の成長機会
• 世界の子宮がん診断市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界の子宮がん診断市場の能力拡大
  • 世界の子宮がん診断市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Siemens Healthcare
• Narang Medical
• F-Hoffmann La Roche
• ESAOTE
• Samsung Medison
• Olympus
• Arquer Diagnostics
• Guzip Biomarkers
• General Electric
• Canon Medical

Uterine Cancer Diagnostics Trends and Forecast

The future of the global uterine cancer diagnostics market looks promising with opportunities in the hospital, diagnostic center, and cancer research center markets. The global uterine cancer diagnostics market is expected to reach an estimated $11.2 billion by 2030 with a CAGR of 9.0% from 2024 to 2030. The major drivers for this market are the increasing cases of uterine cancer, technological advancement in uterine cancer diagnostics, and the growing prevalence of obesity among women worldwide.

Lucintel forecasts that instrument based is expected to witness higher growth over the forecast period due to evolution of diagnostic imaging technology, resulting in heightened precision.

Within this market, hospitals will remain the largest segment due to increasing prevalence of cancer cases, growing demand for minimally invasive advanced screening techniques, and rising investments and funding in cancer diagnostics in hospitals.

North America will remain the largest region over the forecast period due to growing incidence rate of uterine cancer in the US, emphasizing the significance of timely detection and preventive measures to combat cancer, and increasing number of various cancer awareness programs by the government.

Emerging Trends in the Uterine Cancer Diagnostics Market

The market for uterine cancer diagnoses is undergoing tremendous changes due to a range of new trends aimed at improving detection at an earlier stage, accuracy and personalized treatment. These patterns are motivated by technological advancements, increased investments in research, and commitment towards enhancing patient outcomes.

• Latest Imaging Technologies: The use of latest techniques such as high resolution MRI or PET scans is revolutionizing the manner in which uterine cancers are being diagnosed today. These approaches allow for comprehensive analysis of tumor DNA, identifying genetic mutations and alterations that can guide targeted therapies and personalized treatment plans leading to better patient outcomes.
• Molecular Diagnostics And Genomic Profiling: Molecular diagnostics and genomic profiling are becoming crucial aspects in managing uterine cancer. Such tests give insight into the entire tumor DNA allowing identification of genetic mutations/alterations that can guide targeted therapies/individualized treatment plans leading to improved patient survival rates.
• Liquid Biopsies: Liquid biopsies are becoming more and more popular as a non-invasive way of detecting and monitoring uterine cancer. In liquid biopsy, circulating tumor cells or circulating tumor DNA in blood samples can be analyzed to provide an alternative approach to conventional biopsy techniques for easier and more frequent tracking of disease progress and response towards treatment.
• Integration of Artificial Intelligence: The use of AI and machine learning technologies is being employed in diagnostic systems to enhance image analyses from diagnostics data as well as pathology results. Diagnostic accuracy can be improved by identifying patterns or irregularities that may have been missed by humans who review them using AI algorithms. With this technology, there will be better ways to identify uterine cancer at its early age.

Some emerging trends in uterine cancer diagnostics such as advancements in imaging, molecular diagnostics, liquid biopsies, AI integration, and personalized medicine are significantly impacting market dynamics. These trends enhance diagnostic precision, improve early detection rates and support increasingly tailored approaches to treatment all leading to superior patient care provision with associated outcomes for these patients.

Recent Developments in the Uterine Cancer Diagnostics Market

Recent advancements in uterine cancer diagnostics have made a significant progress towards early detection, diagnostic accuracy and personalized treatment approaches. Advanced imaging technologies, molecular diagnostics and novel biomarkers are driving innovations for diagnosing and managing uterine cancer. These developments are aimed at improving patient outcomes and tackling the rising incidence of uterine cancer worldwide.

• Advanced Imaging Technologies: Advances in imaging technologies such as high-resolution MRI and PET scans have improved the capability to detect and accurately characterize uterine tumors. The new technologies provide detailed images of tumor structure and extension thus aiding more accurate diagnosis and treatment planning. Improved sensitivity as well as specificity is very critical for detecting early stage cancers as well as monitoring treatment responses.
• Molecular Diagnostics & Genomic Profiling: The inclusion of molecular diagnostics and genomic profiling into routine practice has allowed a better understanding of the genetic basis underlying uterine cancer. Techniques like next-generation sequencing give an extensive profile of a tumor which helps to identify particular mutations that can help guide targeted therapy decisions leading to more personal treatment plans.
• Liquid Biopsies: The value of liquid biopsies in identifying and monitoring uterine cancer is increasing by the day. Liquid biopsies, which involve analyzing blood samples for circulating tumor cells or DNA, are less invasive than conventional biopsies. These enable continuous observation of disease progression as well as effectiveness of treatment thereby improving patient care and follow-up.
• Biomarker Discovery: New biomarkers linked to uterine cancer have been discovered lately. These biomarkers are employed to develop diagnostic assays that enhance early detection and prognosis. Incorporation of these markers into diagnostic workflows can improve the accuracy of diagnosing uterine cancer as well as stratify patients into risk groups for more personalized treatment approaches.

These developments are making use of advanced imaging technologies, molecular diagnostic tests, liquid biopsies, biomarkers discovery and AI integration to considerably enhance the diagnosis of uterine cancer. Consequently, these breakthroughs help in early detection thereby improving treatment personalization and finally bettering patient outcomes alongside managing this type of cancer.

Strategic Growth Opportunities for Uterine Cancer Diagnostics Market

The uterine cancer diagnostics market provides several strategic growth opportunities driven by increasing demand for early and accurate detection as well as advancements in technology. Key applications in various segments are evolving, thus offering significant prospects for growth through innovation and expanding markets.

• Advanced Imaging Solutions: Investment into advanced imaging solutions like high-resolution MRI scans and PET scans is a major opportunity. Therefore, such innovations provide improved diagnostic capabilities and more precise tumor characterizations. Consequently, spreading their adoption across clinical settings will facilitate earlier identification as well as efficient treatment planning hence pushing market expansion.
• Genomic and Molecular Profiling: Expansion in genomic and molecular profiling technologies development and application present potential areas for growth. Such techniques enable personalized treatment strategies by giving comprehensive profiles regarding tumors. Furthermore, extending access to these profiling tools can improve diagnosis accuracy ensuring positive patient outcomes hence an enlarging segment within the market space.
• Liquid Biopsy Development: The emergence of liquid biopsy technology as a new approach to cancer diagnosis has presented a significant growth avenue. Liquid biopsies, being non-invasive alternatives to traditional tissue biopsies, can lead to enhanced compliance among patients and provide continuous monitoring of cancer progression. Involvement in the liquid biopsy R&D therefore places firms at the forefront of diagnostic innovation.
• Biomarker Research and Integration: Significant growth potential lies in investment in biomarker research and integration of new biomarkers into diagnostic assays. As a result, identification and validation of uterine cancer related biomarkers could drive market expansion through accurate and early detection capabilities.

Advancements in imaging technologies, genomic profiling, liquid biopsy development, biomarker research, and AI integration are representing strategic growth opportunities within uterine cancer diagnostics markets. Such advances offer more accurate diagnosis; enable personalization treatments that are tailored to the molecular profiles of individual cancers; foster expansive capacity building markets ultimately improving patient care as well as outcomes.

Uterine Cancer Diagnostics Market Driver and Challenges

The market for uterine cancer diagnostics is influenced by different technology, economic, and regulatory factors. These are important in determining its dynamics, which include innovation, accessibility, and overall growth.

The factors responsible for driving the uterine cancer diagnostics market include:

1. Technological Progress: Improvement in the accuracy of diagnosis as well as early detection has led to a boost in the utilization of Artificial Intelligence technologies and molecular diagnostics as well as imaging technologies. Such improvements foster personalized treatment and thus promote market growth.

2. Increased Research and Development: However, a major booster of this cancer diagnostic area is rising investment into research and development. This has increased availability of urine tests for detecting HPV infection as well as an indirect way to diagnose cervical cancer through testing for certain types of genetic material found in cells collected from the cervix or vagina using methods that do not require a pelvic examination.

3. Increasing Incidence of Uterine Cancer: Globally increasing cases of uterine cancer have led to search for better diagnosis systems. Therefore, the surge in numbers necessitates prompt and accurate identification tools leading to investments towards new technologies.

Challenges in the uterine cancer diagnostics market are:

1. Regulatory Approvals and Standards: It is a challenge where diagnostic tools are subjected to stringent regulatory requirements and standards. In navigating these regulations, the process may be complicated and time consuming, which can slow down new technology commercialization rate and alter market dynamics in general.

2. Healthcare Access and Equity: Variability in healthcare access and equity across different regions can limit the adoption of advanced diagnostic technologies. Such disparities in accessing quality diagnostics may slow market expansion rates plus impede effective early discovery as well as treatment strategies.

Technological advancements, increased R&D, rising cancer incidence rates, regulatory challenges and differences in healthcare accessibility are among the major drivers of change that shape the uterine cancer diagnostics market. These factors collectively influence market dynamics, shaping innovation, adoption, and overall growth in the field.

List of Uterine Cancer Diagnostics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies uterine cancer diagnostics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the uterine cancer diagnostics companies profiled in this report include-

• Siemens Healthcare
• Narang Medical
• F-Hoffmann La Roche
• Esaote
• Samsung Medison
• Olympus
• Arquer Diagnostics
• Guzip Biomarkers
• General Electric
• Canon Medical

Uterine Cancer Diagnostics by Segment

The study includes a forecast for the global uterine cancer diagnostics by diagnostic type, type, age group, end use, and region.

Uterine Cancer Diagnostics Market by Diagnostic Type [Analysis by Value from 2018 to 2030]:

• Instrument Based
• Procedure Based

Uterine Cancer Diagnostics Market by Type [Analysis by Value from 2018 to 2030]:

• Endometrial Cancer
• Uterine Sarcoma

Uterine Cancer Diagnostics Market by Age Group [Analysis by Value from 2018 to 2030]:

• <30
• 31-40
• 41-50
• 51-60
• >60

Uterine Cancer Diagnostics Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals
• Diagnostic Centers
• Cancer Research Center
• Others

Uterine Cancer Diagnostics Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Uterine Cancer Diagnostics Market

The recent developments in diagnostic approaches of uterine cancer represent a trend towards earlier detection and improved treatment through targeted therapies. This has been seen in the areas of imaging, molecular diagnostics and biomarker research that have improved on diagnostic accuracy as well as patient care. These advances are expected to address the rising prevalence of uterine cancer worldwide and promote individualized therapeutic interventions.

• United States: Advanced imaging modalities such as Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) have been integrated into diagnosing uterine neoplasms. Also, liquid biopsies are an emerging field for non-invasive early detection and monitoring. Besides, AI algorithms are now being used to interpret the images for diagnosis purposes leading to the personalization of treatment strategies.
• China: Genetic testing and molecular diagnostics have gained a foothold in China where it concerns diagnosing endometrial carcinoma. NGS technologies with high throughput sequencing capabilities have made it possible to comprehensively profile tumors thereby facilitating identification of targets for therapy. There is also work done to improve accessibility of these sophisticated diagnostic tools across various localities.
• Germany: Germany leads in novel biomarker assays development for uterus cancer. They are used to detect specific genetic and molecular markers associated with the condition so as to ensure early diagnosis and prognosis. Furthermore, this has necessitated integration of these markers into routine diagnostic workflows to improve overall diagnostic accuracy.
• India: The Indian healthcare sector is increasingly focused on expanding high-quality medical imaging services. This is characterized by new ultrasound technology that produces clearer images of the uterus, including 3D ultrasounds, which enable better detection and characterization of uterine tumors. There have also been efforts towards training of healthcare professionals in the use of such technologies to enhance their capacity for disease diagnosis.
• Japan: Japan has made significant progress on the introduction of precision medicine into the field of uterine cancer diagnostics. Full genomic profiling helps to unravel genetic basis underlying uterine cancer leading to more precise and individualized therapeutic approaches. Besides this, researchers are currently trying to develop new diagnostic biomarkers that can be used for early identification purposes.

Features of the Global Uterine Cancer Diagnostics Market

Market Size Estimates: Uterine cancer diagnostics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Uterine cancer diagnostics market size by various segments, such as by diagnostic type, type, age group, end use, and region in terms of ($B).

Regional Analysis: Uterine cancer diagnostics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different diagnostic types, types, age groups, end uses, and regions for the uterine cancer diagnostics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the uterine cancer diagnostics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the uterine cancer diagnostics market size?

Answer: The global uterine cancer diagnostics market is expected to reach an estimated $11.2 billion by 2030.

Q.2 What is the growth forecast for uterine cancer diagnostics market?

Answer: The global uterine cancer diagnostics market is expected to grow with a CAGR of 9.0% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the uterine cancer diagnostics market?

Answer: The major drivers for this market are the increasing cases of uterine cancer, technological advancement in uterine cancer diagnostics and the growing prevalence of obesity among women worldwide.

Q4. What are the major segments for uterine cancer diagnostics market?

Answer: The future of the uterine cancer diagnostics market looks promising with opportunities in the hospital, diagnostic center, and cancer research center markets.

Q5. Who are the key uterine cancer diagnostics market companies?

Answer: Some of the key uterine cancer diagnostics companies are as follows:

• Siemens Healthcare
• Narang Medical
• F-Hoffmann La Roche
• Esaote
• Samsung Medison
• Olympus
• Arquer Diagnostics
• Guzip Biomarkers
• General Electric
• Canon Medical

Q6. Which uterine cancer diagnostics market segment will be the largest in future?

Answer: Lucintel forecasts that instrument based is expected to witness higher growth over the forecast period due to evolution of diagnostic imaging technology, resulting in heightened precision.

Q7. In uterine cancer diagnostics market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing incidence rate of uterine cancer in the US, emphasizing the significance of timely detection and preventive measures to combat cancer, and increasing number of various cancer awareness programs by the government.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the uterine cancer diagnostics market by diagnostic type (instrument based and procedure based), type (endometrial cancer and uterine sarcoma), age group (<30, 31-40, 41-50, 51-60 , and >60), end use (hospitals, diagnostic centers, cancer research center, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Uterine Cancer Diagnostics Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Uterine Cancer Diagnostics Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Uterine Cancer Diagnostics Market by Diagnostic Type
  • 3.3.1: Instrument Based
  • 3.3.2: Procedure Based
• 3.4: Global Uterine Cancer Diagnostics Market by Type
  • 3.4.1: Endometrial Cancer
  • 3.4.2: Uterine Sarcoma
• 3.5: Global Uterine Cancer Diagnostics Market by Age Group
  • 3.5.1: <30
  • 3.5.2: 31-40
  • 3.5.3: 41-50
  • 3.5.4: 51-60
  • 3.5.5: >60
• 3.6: Global Uterine Cancer Diagnostics Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Diagnostic Centers
  • 3.6.3: Cancer Research Center
  • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Uterine Cancer Diagnostics Market by Region
• 4.2: North American Uterine Cancer Diagnostics Market
  • 4.2.1: North American Uterine Cancer Diagnostics Market by Diagnostic Type: Instrument Based and Procedure Based
  • 4.2.2: North American Uterine Cancer Diagnostics Market by End Use: Hospitals, Diagnostic Centers, Cancer Research Center, and Others
• 4.3: European Uterine Cancer Diagnostics Market
  • 4.3.1: European Uterine Cancer Diagnostics Market by Diagnostic Type: Instrument Based and Procedure Based
  • 4.3.2: European Uterine Cancer Diagnostics Market by End Use: Hospitals, Diagnostic Centers, Cancer Research Center, and Others
• 4.4: APAC Uterine Cancer Diagnostics Market
  • 4.4.1: APAC Uterine Cancer Diagnostics Market by Diagnostic Type: Instrument Based and Procedure Based
  • 4.4.2: APAC Uterine Cancer Diagnostics Market by End Use: Hospitals, Diagnostic Centers, Cancer Research Center, and Others
• 4.5: ROW Uterine Cancer Diagnostics Market
  • 4.5.1: ROW Uterine Cancer Diagnostics Market by Diagnostic Type: Instrument Based and Procedure Based
  • 4.5.2: ROW Uterine Cancer Diagnostics Market by End Use: Hospitals, Diagnostic Centers, Cancer Research Center, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Uterine Cancer Diagnostics Market by Diagnostic Type
  • 6.1.2: Growth Opportunities for the Global Uterine Cancer Diagnostics Market by Type
  • 6.1.3: Growth Opportunities for the Global Uterine Cancer Diagnostics Market by Age Group
  • 6.1.4: Growth Opportunities for the Global Uterine Cancer Diagnostics Market by End Use
  • 6.1.5: Growth Opportunities for the Global Uterine Cancer Diagnostics Market by Region
• 6.2: Emerging Trends in the Global Uterine Cancer Diagnostics Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Uterine Cancer Diagnostics Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Uterine Cancer Diagnostics Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Siemens Healthcare
• 7.2: Narang Medical
• 7.3: F-Hoffmann La Roche
• 7.4: ESAOTE
• 7.5: Samsung Medison
• 7.6: Olympus
• 7.7: Arquer Diagnostics
• 7.8: Guzip Biomarkers
• 7.9: General Electric
• 7.10: Canon Medical